At a glance
ClinicalIndex Comparison RecordPhase 2Active· 315 enrolled
Drug / intervention
Sunvozertinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation
In Brief
A Phase 2 clinical trial evaluating Sunvozertinib for Non-Small Cell Lung Cancer. Active but no longer recruiting, targeting 315 participants across 124 sites in 13 countries.
Detailed Summary
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesArgentina, Australia, Canada, Chile, China, France, Italy, Japan, Malaysia, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2Active
20202021202220232024202520262027
First PostedJun 2019
Enrollment StartJul 2019
Primary CompletionJul 2024
TodayJul 2026
Study CompletionDec 2026
First PostedJun 4, 2019
Enrollment StartJul 9, 2019
Primary CompletionJul 29, 2024
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 7.1 years ago
Interventions
Sunvozertinibdrug
Daily dose of Sunvozertinib